Health Care/Hospital

Peijia Medical Obtained Exclusive License for JenaValve's Trilogy TAVR System for Treating AR in the Greater China Region

SUZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announce its strategic investment and exclusive in-licensing agreement with JenaValve Technology, Inc. Under the terms of the agreement, Peijia has made a cash and equity investment in JenaValve and wil...

2022-01-19 20:00 3334

Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings

* Purchase of Assets and Related Global Commercialization Rights for Oral 9- cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness. * Clinical Stage Asset Has Potential for First Approved Oral Therapy for Leber's Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP) Caused by Mutati...

2022-01-19 19:49 1276

ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data

SHENZHEN, China, Jan. 18, 2022 /PRNewswire/ -- ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study, and demonstrated good saf...

2022-01-19 08:30 1361

Amcor to report Half Year 2022 results

ZURICH, Jan. 18, 2022 /PRNewswire/ -- Amcor plc (NYSE: AMCR; ASX: AMC) will announce its Half Year 2022 results for the six months ended31 December 2021 after the US market closes on Tuesday1 February 2022. A conference call and webcast to discuss the results will be held at 5.30pm US Eastern St...

2022-01-19 06:05 2242

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in itsChina phase ...

2022-01-18 21:00 1351

Akeso's AK117 (CD47 monoclonal antibody) in Combination with AK112 (PD-1/VEGF bi-specific antibody) to Initiate a Phase Ib/II Clinical Trial with or without Chemotherapy for the Treatment of Advanced Malignant Tumors

HONG KONG, Jan. 18, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that Ligufalimab (CD47 monoclonal antibody, research and development code: AK117), the novel immuno-oncology drug independently developed by the Company, combined with Ivonescimab (PD-1/VEGF bi-specific antibody, research an...

2022-01-18 20:44 1848

MindRank Begins IND-enabling Studies of its first AI-designed Drug, 8 Months After Program Initiation

HANGZHOU, China, Jan. 18, 2022 /PRNewswire/ -- MindRank AI, an artificial intelligence (AI) driven biotech company, today announced that the company has nominated a preclinical candidate (PCC) for an important class B GPCR drug target, 8 Months After Program Initiation. Historically, the developm...

2022-01-18 17:17 1181

InnoCare and Keymed Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355

BEIJING, Jan. 18, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the first patient inChina has been dosed in clinical trial of CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two companies, for th...

2022-01-18 14:51 1733

WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility

* WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier quality system is in full compliance with global regulatory requirements. WUXI, China, Jan. 17, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access ...

2022-01-18 10:50 1912

Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules

SHANGHAI, Jan. 17, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter), a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), today announced that it has entered into a worldwide collaboration and exclusive licensing agreement (the "Agreement") with Eli ...

2022-01-18 10:41 1841

CYMBIOTIKA EXPANDS INTO AUSTRALIAN MARKET WITH LAUNCH OF NEW WEBSITE

Leading nutritional supplement brand reaffirms long-term growth in 2022 with international e-commerce platform launch SAN DIEGO, Jan. 18, 2022 /PRNewswire/ -- Cymbiotika, a leading nutritional supplement brand known for creating pure, clinically-backed supplements, today announced the launch of ...

2022-01-18 05:00 1861

CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment ofRichard John Daly ("M...

2022-01-17 21:50 2150

Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate's Global Phase II Clinical Trial in Treating Parkinson's Disease

SHANGHAI, Jan. 17, 2022 /PRNewswire/ -- On January 13, 2022, Green Valley ( Shanghai) Pharmaceuticals Co., Ltd. received the letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of Oligomannate (...

2022-01-17 14:29 1111

Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA

BEIJING and SHANGHAI and BOSTON, Jan. 16, 2022 /PRNewswire/ -- Jacobio's self-developed global first-in-class drug Aurora A inhibitor  JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US. Jacobio plans to initiate a Phase I/IIa clinical trial in pati...

2022-01-17 09:04 1292

China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin

TAIZHOU, China, Jan. 14, 2022 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC ) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of...

2022-01-15 03:30 3520

I-Mab Announces Execution of Senior Management Team Share Purchase Plan

* The execution demonstrates senior management team's tremendous confidence in the Company's innovative globally competitive pipeline and long-term growth prospects SHANGHAI and GAITHERSBURG, MD., Jan. 14, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceut...

2022-01-14 21:00 6415

Leading E-commerce Logistics and Fulfillment Brand NextSmartShip Partners with B2B Medical E-commerce Giant LyncMed

SHENZHEN, China, Jan. 13, 2022 /PRNewswire/ -- NextSmartShip , a world-leading fulfillment service provider for global e-commerce sellers, signed a strategic partnership agreement with LyncMed, a major global e-commerce platform for medical instruments. Under this...

2022-01-13 22:40 1694

United Imaging Announces Construction of a World-leading Intelligent R&D and Manufacturing Complex with an Investment of More Than USD 490 million

SHANGHAI, Jan. 13, 2022 /PRNewswire/ -- Recently, the construction of United Imaging's brand new Manufacturing and R&D base of operations officially kicked off. With a total investment ofUSD 490 million and a planned footprint of about 420,000 square meters, the company is creating a modern campu...

2022-01-13 17:43 1634

LYNC2M Sets to Deliver 41.67 Million Pairs of Nitrile Gloves in February for Its Largest Order in 2022 to Date

LONDON, Jan. 13, 2022 /PRNewswire/ -- Leading Chinese consumer to manufacturer (C2M) medical products supply chain platform, LYNC2M Medical Technology (Beijing ) Co., Ltd. ("LYNC2M"), plans to deliver in February of its first batch of 41.67 million sets of nitrile gloves to UK for a public health ...

2022-01-13 15:34 1771

Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference

INCHEON, South Korea, Jan. 12, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced its sustainable growth plan for this year at the 2022 Annual JP Morgan Healthcare Conference, which is held virtually fromJanuary 10th to 13th with leaders from major pharmaceutical and biopharmaceuti...

2022-01-13 08:52 1741
1 ... 143144145146147148149 ... 257